Dr. Loggers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Suite 3634
Seattle, WA 98109Phone+1 206-606-2018
Summary
- Dr. Elizabeth Loggers is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including University of Washington Medical Center and Seattle Cancer Care Alliance. She received her medical degree from University of Minnesota Medical School and has been in practice 14 years. She specializes in treatment of sarcomas and is expert in hospice and palliative care.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
- Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2006
- University of Minnesota Medical SchoolClass of 2003
Certifications & Licensure
- MT State Medical License 2022 - 2026
- WA State Medical License 2009 - 2026
- ID State Medical License 2022 - 2025
- AK State Medical License 2024 - 2024
- MA State Medical License 2006 - 2010
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer Start of enrollment: 2017 Apr 05
Publications & Presentations
PubMed
- 56 citationsPalliative care, version 2.2021 featured updates to the nccn guidelinesMaria Dans, Jean S. Kutner, Rajiv Agarwal, Justin N. Baker, Jessica Bauman
Journal of the National Comprehensive Cancer Network. 2021-07-28 - 100 citationsNY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.Seth M. Pollack, Achim A. Jungbluth, Benjamin Hoch, Erik A. Farrar, Marie Bleakley
Cancer. 2012-09-15 - 44 citationsNYESO-1/LAGE-1s and prame are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabineSeth M. Pollack, Yonqing Li, Megan J. Blaisdell, Erik A. Farrar, Jeffrey Chou
Plos One. 2012-02-27
Press Mentions
- Fred Hutch at ASCO: Progress in Treating Metastatic Cancer, Hospice Access for Cancer Patients, Use of Machine Learning with CAR T-cell TherapyMay 23rd, 2024
- Risk of Colon Cancer Recurrence in Relation to DiabetesSeptember 22nd, 2019
- Efforts Continue to Expand Immunotherapy Impact in SarcomaJanuary 12th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: